Argentum Wins Invalidation of J&J Unit's Cancer Drug Patent
The U.S. Patent Trial and Appeal Board ruled Wednesday that a patent for Johnson & Johnson's Zytiga prostate cancer drug described an obvious process, invalidating the last remaining patent blocking Argentum...To view the full article, register now.
Already a subscriber? Click here to view full article